WHOOP Adds Galleri Cancer Test, Advanced Labs Open to All

WHOOP is adding GRAIL’s Galleri blood test to its Advanced Labs, putting multi-cancer screening results alongside data on recovery, strain, and sleep in the WHOOP app. The test can detect signals associated with more than 50 types of cancer, but what the company will do with that result alongside your daily health data remains unclear.

What Galleri Actually Detects

Galleri is a blood test that looks for signs of more than 50 types of cancer from a single blood sample.

If the test finds a cancer signal, it also predicts where in the body the cancer may have started. Doctors then use scans, biopsies or other tests to find out whether cancer exists.

How the Test Works

Cancer cells release DNA fragments into the blood. Galleri looks for chemical patterns in them that differ from those found in healthy cells.

A computer model then looks at those patterns and decides whether they look like cancer. If it finds a cancer signal, another model tries to work out which part of the body the cancer came from.

In GRAIL’s tests, it correctly identified the likely source 93.4% of the time.

The Sensitivity Numbers

In GRAIL’s PATHFINDER 2 study, about 35,900 people aged 50 and older were tested. Galleri found 40.4% of cancers overall. For the 12 cancers responsible for about two-thirds of cancer deaths in the US, the detection rate was 73.7%.

An earlier study, called CCGA, reported a higher overall detection rate of 51.5%. The rate was only 16.8% for the earliest-stage cancers and 90.1% for the latest-stage cancers.

CCGA compared people who were already known to have cancer with people known not to have cancer. PATHFINDER 2 instead screened a general population and then followed people to see who actually turned out to have cancer. The second approach is closer to how the test would be used in real life.

Both studies point to the same basic pattern: Galleri is much better at finding cancer when it is more advanced than when it is at an early stage.

The False Alarm Rate

The first point tells you how rarely people without cancer get a positive result. The second tells you what a positive result means for the person receiving it.

1. In PATHFINDER 2, 99.6% of people who did not have cancer received a clear result. GRAIL describes this as a 0.4% false-positive rate, or about one false alarm for every 250 people without cancer.
2. When Galleri did find a cancer signal, cancer was confirmed only 61.6% of the time. About four in 10 people who received a positive result went on to have scans or biopsies that did not find cancer.

 

Regulatory Status

Galleri is not FDA-approved.

It is currently sold as a laboratory-developed test under CLIA rules, which regulate clinical laboratory testing.

GRAIL submitted an application for FDA approval in January 2026. An FDA advisory panel is scheduled to review it on September 23, 2026, about a month after WHOOP’s announcement.

What Galleri Doesn’t Replace

Galleri is meant to be used alongside standard cancer screening, not instead of it. That means you should still have recommended mammograms, colonoscopies, cervical cancer screening and lung cancer screening if you are eligible. A Galleri result does not replace those tests.

GRAIL generally targets adults at higher risk of cancer, typically people aged 50 and older. The test is not intended for people who are pregnant, people under 22, or people already receiving cancer treatment.

Access Through WHOOP

WHOOP introduced Advanced Labs as a membership add-on in 2025. Starting August 18, 2026, anyone can buy Advanced Labs, including Galleri, whether or not they have a WHOOP membership.

GRAIL lists Galleri at $949 when bought directly. WHOOP’s announcement does not make its own price clear, so that is worth checking before publication.

Blood samples are still collected at Quest Diagnostics locations, which have about 2,000 sites across the US. The test results and any follow-up with a clinician are then delivered through the WHOOP app.

Quick answers

Does a negative Galleri result mean I don't have cancer?
No. Galleri is not good at finding every cancer, particularly cancer at an early stage. GRAIL says a negative result does not rule out cancer.

Is Galleri FDA-approved?
No. It is currently sold as a CLIA-regulated laboratory-developed test. An FDA advisory panel is scheduled to review GRAIL’s approval application on September 23, 2026.

Who is Galleri for?
It is intended mainly for adults with a higher risk of cancer, typically people aged 50 and older. GRAIL excludes people who are pregnant, under 22, or currently being treated for cancer.

Last Updated on 22 August 2026 by the5krunner